Doctor holding a tablet

Biotricity builds capacity with University of Calgary and receives ethics approvals for research

New R&D program establishes ambulatory “Wellness” & non-invasive labor monitoring with heart rate variability

NOVEMBER 27, 2018 | BY BIOTRICITY

REDWOOD CITY, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the launch of its 2019 R&D program at the University of Calgary. The Company is initiating a series of investigations using the 1000 Hz fidelity of Bioflux to facilitate ambulatory Heart Rate Variability (HRV) monitoring for maternity and in both major and emergency surgery patients at Rockyview General Hospital in Calgary. Successful results will open up two growing remote monitoring (RPM) markets for Biotricity’s technology: maternal and post-operative remote monitoring.

Building upon its inaugural alpha-test in critically ill patients and ambulatory volunteers, which identified an optimal HRV metric to differentiate between these two groups, Biotricity will compare the utility of short-term pre-operative and long-term post-operative ambulatory HRV monitoring. The Company’s objective is to explore the impact that RPM will have on both outcomes and costs using these high-performance systems.

Patients in stable conditions can be monitored safely from the comfort of home, and with real-time data, physicians will be able to anticipate complications earlier and implement the necessary preventative steps and timely interventions. From a cost-savings perspective, RPM will benefit both patients and hospitals, freeing patients from costly hospital admissions while allowing physicians to better allocate resources to patients with acute and/or critical conditions.

Biotricity will be conducting its R&D program under the fundamental observation that HR and HRV vary directly in healthy patients and indirectly in sicker patients, which should provide real-time insights across a broad range of medical applications. The large and growing market for consumer-grade HRV applications —in utilizations as diverse as athletic optimization and meditation will benefit from medical-grade HRV through the Company’s Biolife device which is expected to be available in 2019.

Biotricity’s non-invasive fetal/maternal HRV and labor contraction monitor development program will further benefit from the expertise added by OB/GYN specialist Dr. Heather Edwards and the signal-processing experience of U of C Biomedical Engineering Professor Dr. Reed Ferber. “We have come a long way from first testing Bioflux in the critically ill and ambulatory populations two years ago to these ground-breaking opportunities today, as Biotricity continues to support research that defends both its IP and our academic freedom,” said Dr. David Liepert, Biotricity Advisory Board member.

“This is a prime example of the way our academic partners work with us, developing Biotricity’s core competencies into world-changing technologies with both clinical and consumer applications,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO.

To learn more, visit www.biotricity.com or follow on

Twitter: @biotricity_inc Facebook: www.facebook.com/biotricity/ or
LinkedIn: www.linkedin.com/company/biotricity-measuring-vitals

About Biotricity Inc.

Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Media contacts

McCoin & Smith Communications Inc.

Chris McCoin
Chris@mccoinsmith.com
508-429-5988

Richard Smith
Rick@mccoinsmith.com
978-433-3304

Investor relations:

Biotricity Investor Relations
Investors@biotricity.com
1.800.951.3348